119 related articles for article (PubMed ID: 24319240)
1. Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses.
Biondi A; Cazzaniga G
Hematology Am Soc Hematol Educ Program; 2013; 2013():612-9. PubMed ID: 24319240
[TBL] [Abstract][Full Text] [Related]
2. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
4. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
5. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
Escherich G; Horstmann MA; Zimmermann M; Janka-Schaub GE;
Leukemia; 2010 Feb; 24(2):298-308. PubMed ID: 20016530
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia.
Mehta PA; Davies SM
Pediatr Blood Cancer; 2007 Jan; 48(1):1-2. PubMed ID: 16642487
[No Abstract] [Full Text] [Related]
7. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
Schrappe M
Radiat Prot Dosimetry; 2008; 132(2):130-3. PubMed ID: 19017727
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
[TBL] [Abstract][Full Text] [Related]
9. Infant acute bilineal leukemia.
Derwich K; Sedek L; Meyer C; Pieczonka A; Dawidowska M; Gaworczyk A; Wachowiak J; Konatkowska B; Witt M; Marschalek R; Szczepański T
Leuk Res; 2009 Jul; 33(7):1005-8. PubMed ID: 19286255
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
11. [Prognosis prediction for childhood acute lymphoblastic leukemia--review].
Liu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):202-6. PubMed ID: 17490555
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation for childhood ALL.
Mehta PA; Davies SM
Bone Marrow Transplant; 2008 Jan; 41(2):133-9. PubMed ID: 17994118
[TBL] [Abstract][Full Text] [Related]
13. [Towards cure for all children with acute lymphoblastic leukemia?].
Baruchel A; Leblanc T; Auclerc MF; Schaison G; Leverger G
Bull Acad Natl Med; 2009 Oct; 193(7):1509-17. PubMed ID: 20669632
[TBL] [Abstract][Full Text] [Related]
14. Therapy for childhood acute lymphoblastic leukemia.
Cassano WF; Eskenazi AE; Frantz CN
Curr Opin Oncol; 1993 Jan; 5(1):42-52. PubMed ID: 8427893
[TBL] [Abstract][Full Text] [Related]
15. Biology of childhood acute lymphoblastic leukemia.
Bhojwani D; Yang JJ; Pui CH
Pediatr Clin North Am; 2015 Feb; 62(1):47-60. PubMed ID: 25435111
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion.
Asselin BL; Gaynon P; Whitlock JA
Curr Opin Oncol; 2013 Dec; 25 Suppl 3():S1-13; quiz S14-6. PubMed ID: 24305505
[TBL] [Abstract][Full Text] [Related]
17. Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia.
Cazzaniga G; Valsecchi MG; Gaipa G; Conter V; Biondi A
Br J Haematol; 2011 Oct; 155(1):45-52. PubMed ID: 21812769
[TBL] [Abstract][Full Text] [Related]
18. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
Tran TH; Hunger SP
Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
[TBL] [Abstract][Full Text] [Related]
19. Relapsed childhood acute lymphoblastic leukaemia.
Bhojwani D; Pui CH
Lancet Oncol; 2013 May; 14(6):e205-17. PubMed ID: 23639321
[TBL] [Abstract][Full Text] [Related]
20. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui CH; Mullighan CG; Evans WE; Relling MV
Blood; 2012 Aug; 120(6):1165-74. PubMed ID: 22730540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
